Search - tctmd.com

Displaying 361 - 380 of 1423

Sort: Relevancy | Date

Presentation TCT 2017

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Presenter: Robert A. Harrington, Sanjay Kaul, Schuyler Jones

October 30, 2017

Presentation TCT 2017

Does Pedal Loop Angioplasty Improve the Outcomes of Patients With CLI?

Presenter: Subhash Banerjee, Arthur C. Lee

October 30, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

Risk Score Development, Validation, Precision, Discrimination, and Utility

Presenter: Robert A. Harrington, Sanjay Kaul, Davide Capodanno

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Presentation TCT 2017

Understanding Surgical Aortic Valve Anatomy: Implications for Valve-in-Valve Therapy

Presenter: Vinayak Bapat

October 30, 2017

Presentation TCT 2017

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

Presenter: Elazer R. Edelman, Paul A. Sobotka

October 30, 2017

Presentation TCT 2017

The NOTION 2 Low-risk Trial in Younger Patients

Presenter: Lars Sondergaard

October 30, 2017

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

Presentation TCT 2017

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Presenter: Robert A. Harrington, Sanjay Kaul, Giuseppe Biondi-Zoccai

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

The UK All-comer TAVI Study

Presenter: Neil E. Moat

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Presenter: Michael Böhm, Thomas F. Luscher, Robert S. Schwartz

October 30, 2017

Presentation TCT 2017

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Presentation TCT 2017

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Presenter: Thomas Walther

October 30, 2017

Advertisement

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Does Pedal Loop Angioplasty Improve the Outcomes of Patients With CLI?

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Risk Score Development, Validation, Precision, Discrimination, and Utility

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Understanding Surgical Aortic Valve Anatomy: Implications for Valve-in-Valve Therapy

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

The NOTION 2 Low-risk Trial in Younger Patients

The Evolut R Low-risk Trial

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

The PARTNER 3 Low-risk Trial

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

The UK All-comer TAVI Study

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content